back to news

Simple Blood Test May Be As Accurate As Spinal Fluid Test For Diagnosing Parkinson’s

HELIO

Hansson O, et al. Neurology. 2017;doi:10.1212/WNL.0000000000003680.

The blood neurofilament light chain protein can be used to distinguish Parkinson’s disease from atypical parkinsonism disorders such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, according to research recently published in Neurology.

“Our findings are exciting because when Parkinson’s or an atypical parkinsonism disorder is suspected, one simple blood test will help a physician to give their patient a more accurate diagnosis,” according to Oskar Hansson, MD, PhD, associate professor, Lund University, Sweden. “These atypical parkinsonism disorders are rare, but they generally progress much faster and are more likely to be the cause of death than Parkinson’s disease, so it’s important for patients and their families to receive the best care possible and to plan for their future needs.”

Hansson and colleagues included three independent prospective cohorts in their study: the Lund (n = 278) and London (n = 117) cohorts, made up of healthy controls and patients with Parkinson’s disease, progressive supranuclear palsy, corticobasal syndrome, and multiple system atrophy; and an early disease cohort (n = 109) of patients with these conditions for 3 years or less. The patients’ blood neurofilament light chain concentration was measured using an ultrasensitive single molecule array method known as Simoa (Quanterix). This tool, as Healio Family Medicine has previously reported, uses single molecule measurements to access previously undetectable proteins in blood, advancing and accelerating disease diagnoses and treatment.

Read the rest of the article at helio.com